Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors

Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors

Background/Objective To assess safety/efficacy of tofacitinib and tumor necrosis factor inhibitors (TNFi) in patients from Latin America (LATAM) in ORAL Surveillance. Methods In ORAL Surveillance, 4362 patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor re...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gustavo Citera, Eduardo Mysler, Adriana María Kakehasi, Virginia Pascual‐Ramos, Walter Massón, Mary Jane Cadatal, Jose L. Rivas, Farzad Sheibanie, Claudia Helling, Darío Ponce de León
Médium: Artigo
Jazyk:angličtina
Vydáno: 2024
On-line přístup:https://doi.org/10.1097/rhu.0000000000002106
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1097/rhu.0000000000002106

Podobné jednotky